Ceritinib CAS 1032900-25-6

Product Description:

Product Name: Ceritinib CAS NO: 1032900-25-6

Synonyms:

5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine;

Ceritinib (LDK378);

LDK378||LDK-378;

hemical & Physical Properties:

Appearance: Off-white solid

Assay :≥99.0%

Density: 1.251±0.06 g/cm3 (Predicted)

Boiling Point: 720.7±70.0℃ (Predicted)

PKa: 10.16±0.10 (Predicted)

Flash Point: 389.6±35.7℃

Vapor Pressure: 0.0±2.3 mmHg at 25℃

Index of Refraction: 1.595

Ceritinib (INN, trade name Zykadia) is a drug for the treatment of a specific type of lung cancer. It is an anaplastic lymphoma kinase (ALK) inhibitor. It was developed by Novartis. It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients that failed treatment with crizotinib. It is a more effective, but more toxic, alternative to traditional platinum-based chemotherapies. Ceritinib was found at physiological concentrations to inhibit ALK, insulin-like growth factor 1 receptor (IGF-1R), and ROS1.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.